Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Liquidia Technologies, Inc. (LQDA : NSDQ)

• Company Description    Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $5.79 Daily Weekly Monthly 20 Day Moving Average: 615,390 shares Shares Outstanding: 64.34 (millions) Market Capitalization: $372.55 (millions) Beta: 0.33 52 Week High: $7.78 52 Week Low: $2.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.51% 17.70% 12 Week -2.03% 7.70% Year To Date 18.89% 45.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 419 DAVIS DRIVE SUITE 100 - MORRISVILLE,NC 27560 USA ph: 919-328-4400 fax: - ir@liquidia.com http://www.liquidia.com

• General Corporate Information    Officers Neal Fowler - Chief Executive Officer and Director Stephen Bloch - Chairman of the Board of Directors Richard D. Katz - Chief Financial Officer Katherine Rielly-Gauvin - Director Joanna Horobin - Director Peer Information Liquidia Technologies, Inc. (CORR.) Liquidia Technologies, Inc. (RSPI) Liquidia Technologies, Inc. (CGXP) Liquidia Technologies, Inc. (BGEN) Liquidia Technologies, Inc. (GTBP) Liquidia Technologies, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 53635D202 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 64.34 Most Recent Split Date: (:1) Beta: 0.33 Market Capitalization: $372.55 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.98 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 28.09 EPS Growth vs. Year Ago Period: -42.86% vs. Previous Quarter: -30.43% Sales Growth vs. Year Ago Period: 13.23% vs. Previous Quarter: 8.62% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - - Quick Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - - Operating Margin 03/31/22 - -311.70 12/31/21 - -269.01 09/30/21 - -376.74 Net Margin 03/31/22 - -311.71 12/31/21 - -269.01 09/30/21 - -376.75 Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - - 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©